The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective

The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective

The emergence of immunotherapy, particularly programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1) produced profound transformations for treating non-small cell lung cancer (NSCLC). Nevertheless, not all NSCLC patients can benefit from immunotherapy in clinical practice. In addit...

Full description

Bibliographic Details
Main Authors:	Shuai Liang, Hanyu Wang, Haixia Tian, Zhicheng Xu, Min Wu, Dong Hua, Chengming Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Series:	Frontiers in Immunology
Subjects:	non-small cell lung cancer (NSCLC) immunotherapy prognostic biological markers anti-PD-(L)1 review
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1249980/full

Similar Items

Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
by: Danilo Rocco, et al.
Published: (2023-09-01)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
by: Wolfgang M. Brueckl, et al.
Published: (2020-12-01)

Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges
by: Débora Dummer Meira, et al.
Published: (2023-10-01)

Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer
by: Chang JIANG, et al.
Published: (2022-01-01)

Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors
by: Samuel A. Kareff, MD, MPH, et al.
Published: (2021-04-01)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
by: Kim A. Brogden, et al.
Published: (2018-02-01)

Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
by: Magdalena Knetki-Wróblewska, et al.
Published: (2023-03-01)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
by: Xin-wei Qiao, et al.
Published: (2020-09-01)

Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
by: Jingsi Dong, et al.
Published: (2019-03-01)

PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
by: Foteinos-Ioannis Dimitrakopoulos, et al.
Published: (2020-05-01)

ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
by: Yao Chen, et al.
Published: (2020-09-01)

Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer
by: Luis Miguel Chinchilla-Tábora, et al.
Published: (2024-02-01)

Recent Advances in Immunotherapy in Metastatic NSCLC.
by: Pranshu Bansal, et al.
Published: (2016-11-01)

Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
by: Anna Grenda, et al.
Published: (2022-07-01)

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC
by: Jie Mei, et al.
Published: (2022-07-01)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
by: Marie-Hélène Denault, et al.
Published: (2021-11-01)

The prognostic and predictive roles of plasma C‐reactive protein and PD‐L1 in non‐small cell lung cancer
by: Saara Kuusisalo, et al.
Published: (2023-08-01)

The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer
by: Michał Szczyrek, et al.
Published: (2022-07-01)

Immunotherapy in the treatment of non-small cell lung cancer (NSCLC) - analysis of epidemiology and cure - review
by: Kinga Ruszel, et al.
Published: (2020-08-01)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
by: Anand Khadse, et al.
Published: (2022-04-01)

Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
by: Fabio Pagni, et al.
Published: (2020-07-01)

The Landscape of Immunotherapy Resistance in NSCLC
by: Daniele Frisone, et al.
Published: (2022-04-01)

The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy
by: Miaomiao Gou, et al.
Published: (2021-06-01)

Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC
by: Amine Bouhamama, et al.
Published: (2023-05-01)

Targeting the ERβ/HER Oncogenic Network in <i>KRAS</i> Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy
by: Abdulaziz A. Almotlak, et al.
Published: (2021-12-01)

Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis
by: Hesti Platini, et al.
Published: (2022-08-01)

Erratum: The landscape of immunotherapy resistance in NSCLC
by: Frontiers Production Office
Published: (2023-04-01)

<sup>18</sup>F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
by: Giulia Polverari, et al.
Published: (2020-05-01)

Fascaplysin Induces Apoptosis and Ferroptosis, and Enhances Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) by Promoting PD-L1 Expression
by: Lianxiang Luo, et al.
Published: (2022-11-01)

Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression
by: Timothy Rajakumar, MD, PhD, et al.
Published: (2022-08-01)

Research Progress of Immunotherapy and Prognostic Markers in Small Cell Lung Cancer
by: Qingyi WANG, et al.
Published: (2020-03-01)

Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients
by: Luigi Della Gravara, et al.
Published: (2021-06-01)

Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC
by: Ana Oitabén, et al.
Published: (2022-05-01)

Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
by: Angelo Borsarelli Carvalho Brito, et al.
Published: (2021-04-01)

Advances in Dynamic Monitoring of Immune Checkpoint Inhibitors as the Prognostic Markers for Advanced Non-small Cell Lung Cancer
by: DAI Liyuan, et al.
Published: (2022-03-01)

Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy
by: Jair Bar, et al.
Published: (2024-02-01)

Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer
by: Frederik A. van Delft, et al.
Published: (2022-10-01)

IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer
by: Hua Liao, et al.
Published: (2023-11-01)

MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients?
by: Anna Grenda, et al.
Published: (2024-02-01)

Frontier and Future of Immunotherapy for Pancreatic Cancer
by: ZHOU Wence, et al.
Published: (2023-04-01)